Antimicrobial resistance of clinical Streptococcus pyogenes isolates in Russia: the results of multicenter epidemiological study «PEHASus 2014–2017»

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):40-45

Type
Original Article

Objective.

To evaluate antimicrobial resistance patterns of clinical Streptococcus pyogenes isolates from different regions of Russia during 2014–2017.

Materials and Methods.

A total of 792 clinical S. pyogenes isolates from 14 Russian cities were included in the study. Susceptibility testing was performed using reference broth microdilution method (ISO 207761:2006). Susceptibility testing results were interpreted using EUCAST v.10.0 breakpoints.

Results.

Penicillin G was active against all tested isolates with the MIC50–90 values of 0.016 mg/l and the highest MIC value of 0.25 mg/l. No resistance to linezolid, tedizolid and vancomycin were observed. Respiratory fluoroquinolones, moxifloxacin and levofloxacin, showed a high activity with the only 0.3% and 0.8% of resistant isolates, respectively. Almost all isolates (99.9%) were susceptible to trimethoprim/ sulfamethoxazole. The resistance rates to 14- and 15-membered macrolides varied from 12.1% to 17.2%. The only 2.4% of isolates were resistant to clindamycin. Resistance to chloramphenicol was 6.1%, to tetracycline – 17.2%.

Conclusions.

The comparison of this study results with the previously published Russian data on antimicrobial resistance of S. pyogenes shows there were no significant changes in the susceptibility of this pathogen over the past two decades, with the exception of macrolides. The growing resistance to 14and 15-membered macrolides raises a question on the further use of this antibiotic class for the empiric treatment of streptococcal infections in Russia.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0